Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell disease.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
14 Mar 2024
14 Mar 2024
Historique:
received:
06
12
2023
accepted:
26
02
2024
revised:
19
02
2024
pubmed:
15
3
2024
medline:
15
3
2024
entrez:
15
3
2024
Statut:
aheadofprint
Résumé
Allogeneic stem cell transplantation (Allo-SCT) is the only rapidly available curative treatment modality in patients with severe sickle cell disease (SCD). The development of reduced-toxicity myeloablative conditioning (RT-MAC) regimen and the use of partially matched family donors with post-transplantation cyclophosphamide (PT-Cy) have widened the access to Allo-SCT. Antibodies against donor-specific HLA (DSA) increase the risk of engraftment failure in HLA mismatched Allo-SCT. We report the results of five patients with SCD, whereas three with DSA, who underwent an unmanipulated haploidentical stem cell transplantation (Haplo-SCT) after a busulfan-based RT-MAC regimen with PT-Cy. To reduce the risk of engraftment failure, a sequential two courses pharmacological pre-transplant immune suppression (PTIS) phase was added prior to the conditioning regimen. All patients engrafted successfully. The procedure was well tolerated. None of the patients developed acute GVHD, whereas one developed moderate chronic GVHD. After a median follow-up of 5 years (range, 2.2-9), all patients are free of pain with excellent quality of life. Our report shows that Haplo-SCT after a RT-MAC regimen is feasible and safe with stable long-term engraftment and excellent disease control. The risk of graft failure can be abrogated by adding a PTIS phase prior to initiating the conditioning regimen.
Identifiants
pubmed: 38486114
doi: 10.1038/s41409-024-02257-8
pii: 10.1038/s41409-024-02257-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N. Engl J Med. 2017;377:305.
pubmed: 28723338
Gluckman E, Cappelli B, Bernaudin F, Labopin M, Volt F, Carreras J, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129:1548–56.
pubmed: 27965196
pmcid: 5356458
doi: 10.1182/blood-2016-10-745711
Lanzkron S, Carroll CP, Haywood C. Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Rep. Wash DC 1974. 2013;128:110–6.
Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Med (Baltim). 2005;84:363–76.
doi: 10.1097/01.md.0000189089.45003.52
Fitzhugh CD, Lauder N, Jonassaint JC, Telen MJ, Zhao X, Wright EC, et al. Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol. 2010;85:36–40.
pubmed: 20029950
doi: 10.1002/ajh.21569
Eapen M, Brazauskas R, Walters MC, Bernaudin F, Bo-Subait K, Fitzhugh CD, et al. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematol. 2019;6:e585–96.
pubmed: 31495699
pmcid: 6813907
doi: 10.1016/S2352-3026(19)30154-1
Bernaudin F, Dalle JH, Bories D, Peffault de Latour R, Robin M, Bertrand Y, et al. Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France. Haematologica. 2020;105:91–101.
Vermylen C, Cornu G, Ferster A, Brichard B, Ninane J, Ferrant A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transpl. 1998;22:1–6.
doi: 10.1038/sj.bmt.1701291
Walters MC, Patience M, Leisenring W, Eckman JR, Scott JP, Mentzer WC, et al. Bone marrow transplantation for sickle cell disease. N. Engl J Med. 1996;335:369–76.
pubmed: 8663884
doi: 10.1056/NEJM199608083350601
Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood. 2000;95:1918–24.
pubmed: 10706855
Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007;110:2749–56.
pubmed: 17606762
doi: 10.1182/blood-2007-03-079665
van Besien K, Bartholomew A, Stock W, Peace D, Devine S, Sher D, et al. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transpl. 2000;26:445–9.
doi: 10.1038/sj.bmt.1702518
Hoppe CC, Walters MC. Bone mbone marrow transplantation for symptomatic sickle cell diseasearrow transplantation in sickle cell anemia. Curr Opin Oncol. 2001;13:85–90.
pubmed: 11224704
doi: 10.1097/00001622-200103000-00001
Hsieh MM, Fitzhugh CD, Weitzel RP, Link ME, Coles WA, Zhao X, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA. 2014;312:48–56.
pubmed: 25058217
pmcid: 4698790
doi: 10.1001/jama.2014.7192
Iannone R, Casella JF, Fuchs EJ, Chen AR, Jones RJ, Woolfrey A, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2003;9:519–28.
doi: 10.1016/S1083-8791(03)00192-7
Horan JT, Liesveld JL, Fenton P, Blumberg N, Walters MC. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transpl. 2005;35:171–7.
doi: 10.1038/sj.bmt.1704745
Shenoy S, Eapen M, Panepinto JA, Logan BR, Wu J, Abraham A, et al. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016;128:2561–7.
pubmed: 27625358
pmcid: 5123194
doi: 10.1182/blood-2016-05-715870
Mentzer WC, Heller S, Pearle PR, Hackney E, Vichinsky E. Availability of related donors for bone marrow transplantation in sickle cell anemia. Am J Pediatr Hematol Oncol. 1994;16:27–9.
pubmed: 8311169
Ruggeri A, Eapen M, Scaravadou A, Cairo MS, Bhatia M, Kurtzberg J, et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2011;17:1375–82.
doi: 10.1016/j.bbmt.2011.01.012
Adamkiewicz TV, Szabolcs P, Haight A, Baker KS, Staba S, Kedar A, et al. Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatr Transpl. 2007;11:641–4.
doi: 10.1111/j.1399-3046.2007.00725.x
Kamani NR, Walters MC, Carter S, Aquino V, Brochstein JA, Chaudhury S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2012;18:1265–72.
doi: 10.1016/j.bbmt.2012.01.019
Robinson TM, O’Donnell PV, Fuchs EJ, Luznik L. Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol. 2016;53:90–7.
pubmed: 27000732
pmcid: 4806368
doi: 10.1053/j.seminhematol.2016.01.005
Luznik L, Jones RJ, Fuchs EJ. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol. 2010;17:493–9.
pubmed: 20827187
pmcid: 3138214
doi: 10.1097/MOH.0b013e32833eaf1b
Bolaños-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120:4285–91.
pubmed: 22955919
pmcid: 3507140
doi: 10.1182/blood-2012-07-438408
Socié G, Rizzo JD. Second solid tumors: screening and management guidelines in long-term survivors after allogeneic stem cell transplantation. Semin Hematol. 2012;49:4–9.
pubmed: 22221779
doi: 10.1053/j.seminhematol.2011.10.013
Rizzo JD, Curtis RE, Socié G, Sobocinski KA, Gilbert E, Landgren O, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009;113:1175–83.
pubmed: 18971419
pmcid: 2635083
doi: 10.1182/blood-2008-05-158782
Tichelli A, Beohou E, Labopin M, Socié G, Rovó A, Badoglio M, et al. Evaluation of second solid cancers after hematopoietic stem cell transplantation in european patients. JAMA Oncol. 2019;5:229–35.
pubmed: 30476975
doi: 10.1001/jamaoncol.2018.4934
de la Fuente J, Dhedin N, Koyama T, Bernaudin F, Kuentz M, Karnik L, et al. Haploidentical bone marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2019;25:1197–209.
doi: 10.1016/j.bbmt.2018.11.027
Kassim AA, Walters MC, Eapen M, Ritzau N, Smith M, Solh MM, et al. Reduced intensity haploidentical bone marrow transplantation in adults with severe sickle cell disease: BMT CTN 1507. Blood. 2023;142:LBA-4–LBA-4.
doi: 10.1182/blood-2023-192022
Alasbali R, Alzahrani M, Alhayli S, Rasheed W, Akhom P, Wilkerson K, et al. Excellent outcomes of HLA matched related donor transplant for adults with severe sickle cell disease using a non-myeloablative conditioning with thiotepa and post-transplant cyclophosphamide: multi-center international experience. Blood. 2023;142:1042–1042.
doi: 10.1182/blood-2023-189914
Anurathapan U, Hongeng S, Pakakasama S, Sirachainan N, Songdej D, Chuansumrit A, et al. Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors. Bone Marrow Transpl. 2016;51:813–8.
doi: 10.1038/bmt.2016.7
Anurathapan U, Hongeng S, Pakakasama S, Songdej D, Sirachainan N, Pongphitcha P, et al. Hematopoietic stem cell transplantation for severe thalassemia patients from haploidentical donors using a novel conditioning regimen. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2020;26:1106–12.
doi: 10.1016/j.bbmt.2020.01.002
Hongeng S, Anurathapan U, Pakakasama S, Songdej D, Pongphitcha P, Sirachainan N, et al. Haploidentical transplantation in severe thalassemia patients using pre-transplant immunosuppression (PTIS) and Post-Transplant Cyclophosphamide. Transpl Cell Ther. 2023;29:S290–1.
doi: 10.1016/S2666-6367(23)00452-9
Bhatia M, Kolva E, Cimini L, Jin Z, Satwani P, Savone M, et al. Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2015;21:666–72.
doi: 10.1016/j.bbmt.2014.12.007
Saraf SL, Ghimire K, Patel P, Sweiss K, Gowhari M, Molokie RE, et al. Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease. PloS One. 2020;15:e0229710.
pubmed: 32101564
pmcid: 7043749
doi: 10.1371/journal.pone.0229710
Anurathapan U, Pakakasama S, Mekjaruskul P, Sirachainan N, Songdej D, Chuansumrit A, et al. Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2014;20:2066–71.
doi: 10.1016/j.bbmt.2014.07.016
Gladstone DE, Zachary AA, Fuchs EJ, Luznik L, Kasamon YL, King KE, et al. Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2013;19:647–52.
doi: 10.1016/j.bbmt.2013.01.016
Ciurea SO, Cao K, Fernadez-Vina M, Kongtim P, Malki MA, Fuchs E, et al. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transpl. 2018;53:521–34.
doi: 10.1038/s41409-017-0062-8
Angelucci E, Pilo F. Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major. Ann N. Y Acad Sci. 2016;1368:115–21.
pubmed: 26999450
doi: 10.1111/nyas.13027
Wiebking V, Hütker S, Schmid I, Immler S, Feuchtinger T, Albert MH. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease. Ann Hematol. 2017;96:1373–7.
pubmed: 28573314
doi: 10.1007/s00277-017-3030-x
Pawlowska AB, Cheng JC, Karras NA, Sun W, Wang LD, Bell AD, et al. HLA haploidentical stem cell transplant with pretransplant immunosuppression for patients with sickle cell disease. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2018;24:185–9.
doi: 10.1016/j.bbmt.2017.08.039
Aydin M, Dovern E, Leeflang MMG, de la Fuente J, Kassim AA, Biemond BJ, et al. Haploidentical allogeneic stem cell transplantation in sickle cell disease: a systematic review and meta-analysis. Transpl Cell Ther. 2021;27:1004.e1–1004.e8.
doi: 10.1016/j.jtct.2021.09.009
Leonard A, Tisdale JF A new frontier: FDA approvals for gene therapy in sickle cell disease. Mol Ther. 2024 Jan;S1525001624000157.